Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 23, 2024 12:58 ET | Source: Io Therapeutics, Inc.

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

Scientists at Dalhousie University and Io Therapeutics publish data on effectiveness of IRX4204 in reversing demyelination in a model of multiple sclerosis
December 11, 2024 16:35 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor

Io Therapeutics announces presentation of data on its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer.
November 08, 2024 14:51 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers

Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers
September 18, 2024 11:07 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
July 16, 2024 09:26 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)

Io Therapeutics, Inc., presented today studies supporting potential use of its novel drug IRX4204 for treatment of amyotrophic lateral sclerosis (ALS)
July 09, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
July 08, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound

Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
September 12, 2023 00:43 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses

SPRING, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., announced today the publication in Scientific Reports – Nature Publishing Group, of results from studies done with the...
September 16, 2016 07:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. Reports Data Demonstrating That the Company's Candidate Treatment for Multiple Sclerosis, IRX4204, Promotes Repair of Damaged Myelin

SANTA ANA, CA--(Marketwired - Sep 16, 2016) - Io Therapeutics, Inc., today, reported data demonstrating that the company's experimental rexinoid nuclear receptor (RXR) agonist compound, IRX4204,...
August 03, 2015 08:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. Announces Sponsored Research Agreement With the National Multiple Sclerosis Society Fast Forward Program

SANTA ANA, CA--(Marketwired - Aug 3, 2015) - Io Therapeutics, Inc. announced today the receipt of funding from the National Multiple Sclerosis Society through Fast Forward to support further...

Next Page keyboard_arrow_right